Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants상업용 Anti-SARS-CoV-2 수용체 결합 도메인 항체 테스트와 화학발광 환원 중화 테스트의 상관관계 및 항체의 새로운 변이체 검출 가능Research Article Published on 2021-12-012022-09-10 Journal: Microbiology Spectrum [Category] SARS, 변종, 진단, 치료기술, [키워드] 95% confidence interval Accuracy acquisition acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-RBD anti-receptor-binding domain Antibody test antibody test result antibody tests B.1.1.7 B.1.351 B.1.351 variant B.1.351 variants biohazard clinical laboratory close contact comparable convalescent convalescent COVID-19 patients convalescent phase Coronavirus-2 correlated correlation COVID-19 COVID-19 patient COVID-19 patients Critical defined detection diagnostic disease onset displaying Efficacy episode episode of Evidence evidence of functional healthy individual high throughput identify immune response Immunity indicate Laboratory lead neutralization Neutralizing Neutralizing activity Neutralizing antibodies Neutralizing titer neutralizing titers optimization Patient PCR-negative positive result proof protective immunity provide Pseudotyped virus Pseudotyped viruses Quantitative RBD Receptor-binding domain recognizing reduction respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Seroconversion serological test Serological tests serology serum sample serum samples Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Strong symptomatic Test test validity Vaccine vaccine efficacy Validity variant variants virus viruses wild-type [DOI] 10.1128/Spectrum.00560-21 PMC 바로가기 [Article Type] Research Article
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesResearch Paper Published on 2021-12-012022-10-30 Journal: Journal of Immunological Methods [Category] COVID-19, SARS, [키워드] 2019-nCoV/USA-WA1/2020 Abstract antibody Antibody titer Antigen assays clinical clinical sample Complete control sample convalescent COVID COVID-19 Efficacy ELISA ELISAs Endpoint evaluate evaluated functional healthy donor human clinical trials humoral humoral immune response Humoral immunity IgA IgG IgG1 IgG3 IgG4 IgM Image in vitro individuals inhibiting lentivirus linear linearity magnitude methodology neutralization Neutralizing Neutralizing titer pandemic plaque reduction neutralization plasma PRNT pseudovirus Pseudovirus neutralization assay Qualification RBD Receptor binding domain Replication response SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 vaccine the SARS-CoV-2 the Spike the vaccine trials trimeric spike Vaccine WHO [DOI] 10.1016/j.jim.2021.113160 PMC 바로가기 [Article Type] Research Paper
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern불활성화 백신 2회 투여 후 재조합 단백질 소단위 백신 부스터는 항-RBD 반응을 극적으로 향상시키고 SARS-CoV-2 및 우려 변이체에 대한 역가를 중화Letter to the Editor Published on 2021-11-232022-09-11 Journal: Cell Research [Category] MERS, SARS, 변종, 진단, [키워드] anti-RBD Biological techniques booster concern immunology Inactivated vaccine Neutralizing titer Recombinant protein response SARS-CoV-2 subunit Vaccine [DOI] 10.1038/s41422-021-00590-x PMC 바로가기 [Article Type] Letter to the Editor
Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 VaccineArticle Published on 2021-11-222022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 진단, [키워드] ACE2 activity acute respiratory syndrome age angiotensin-converting enzyme 2 antibodies antibody B.1.1.7 B.1.351 Beta Clover competitive binding concern coronavirus coronavirus disease COVID-19 cross-neutralization cross-reactive Day demonstrated dose dose-dependent increase Gamma IgG IgG antibodies immune response immunogenicity Immunoglobulin neutralizing antibody Neutralizing titer P.1 persistence phase 1 study Placebo prefusion prevalent reported response SARS-CoV-2 SCB-2019 sera Spike protein titer vaccination Vaccine vaccine candidate variants of concern Volunteer waned wild-type SARS-CoV-2 Wuhan-Hu-1 [DOI] 10.1093/infdis/jiab447 PMC 바로가기
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors종양 괴사 인자-α 억제제를 투여받는 mRNA 백신 접종 개인의 혈청에서 SARS-CoV-2 B.1.617.2 델타 바이러스에 대한 항체 활성 감소Clinical and Translational Article Published on 2021-11-182022-09-14 Journal: Med (New York, N.Y.) [Category] SARS, 변종, 진단, 치료법, [키워드] Abstract acute respiratory syndrome administration Alpha Analysis antibody Antibody Response B.1.351 B.1.617.2 BNT162b2 BNT162b2 mRNA vaccine center chronic inflammatory disease Cohort Context coronavirus coronavirus disease COVID-19 dose evaluated Fc effector functions finding function capacity funding immunization Immunocompromised immunocompromised individuals immunogenic Immunosuppression immunosuppressive immunosuppressive drug in healthy individuals individual individuals inhibitor inhibitors Innovation less longitudinal lowest monoclonal antibodies monotherapy mRNA vaccine Necrosis neutralization Neutralizing neutralizing antibody Neutralizing antibody titer Neutralizing titer neutralizing titers NIAID Pfizer populations Prevent Prophylaxis protective immunity receiving recipients reduced reductions in required response SARS-CoV-2 SARS-COV-2 infection serum serum antibody serum antibody response Serum neutralizing antibody severe disease strain supported susceptible tested Therapies therapy threshold TNF inhibitors TNF-α treated tumor necrosis factor-α vaccination Vaccine vaccine dose variant variants variants of concern virus [DOI] 10.1016/j.medj.2021.11.004 PMC 바로가기 [Article Type] Clinical and Translational Article
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant고분자 글리코 보조제에 대한 접합을 통한 SARS-CoV-2 항원에 대한 강력한 세포 및 체액 면역 생성Article Published on 2021-11-012022-09-12 Journal: Biomaterials [Category] MERS, SARS, 진단, [키워드] activate activated adjuvant adjuvants amplified antibody Antigen antigen-presenting cell antigen-specific antibody APCS B cells caused CD4 CD8 cells cellular composed convalescent human serum COVID-19 COVID-19 vaccine Disease model effective elicit follicular generate Generation Glycopolymers Humoral immunity Humoral response IgGs immune response increase in long-lasting mice monomer Neutralizing Neutralizing titer platform Polymer-protein conjugates Polymeric glyco-adjuvant producing Protein protein antigen receptor robust SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 virus secreting shown Spread subunit Subunit vaccine Subunit vaccine formulation. T cell responses T cells the Spike the vaccine TLR7 Toll-like receptor triggering vaccination Vaccine vaccine candidate wild-type yielding [DOI] 10.1016/j.biomaterials.2021.121159 PMC 바로가기 [Article Type] Article
Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma고역가 회복기 혈장으로 치료한 SARS-CoV-2 폐렴 환자의 말초혈액 내 사이토카인 및 케모카인 상승Research Article Published on 2021-10-292022-09-12 Journal: PLoS Pathogens [Category] MERS, SARS, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome addition administration Blood caused chemokine chemokines Clinical course clinical trial Cohort Concentration conducted contribute convalescent convalescent plasma Convalescent plasma therapy correlated Course COVID-19 COVID-19 pneumonia CRP cytokine Cytokine storm syndrome Cytokines Day Deterioration Disease progression Donor donors Efficacy elevated Elevation elevations evaluate fatality foundation healthy controls Hospitalization Hospitalized hospitalized COVID-19 hospitalized COVID-19 patient hospitalized COVID-19 patients IIa immune immune activation immune response IMPROVE increase in Inflammatory Inflammatory cytokines infusion institution Lung pathology mechanical ventilation MIP-1α MIP-1β Neutralizing antibodies neutralizing antibody Neutralizing titer observation outcomes pandemic Patient patients patients hospitalized patients with SARS-CoV-2 Peripheral blood phase plasma plasma sample plasma samples Pneumonia Potential biomarker potential biomarkers receive recipient recipients respiratory distress Respiratory distress syndrome resulting SARS-CoV-2 coronavirus SARS-COV-2 infection SARS-CoV-2 virus significant difference syndrome the cytokine storm the disease the patient the SARS-CoV-2 virus the timing track transfer treat treated Treatment unique virus while with COVID-19 [DOI] 10.1371/journal.ppat.1010025 PMC 바로가기 [Article Type] Research Article
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452IgG-Fc 융합 코로나19 서브유닛 백신 AKS-452 개발Article Published on 2021-10-292022-09-11 Journal: Vaccine [Category] MERS, SARS, 변종, 진단, [키워드] adjuvant adjuvants African Antigen APCS augmentation B.1.351 Cell cells clinical development Clinical studies clinical study clinical symptom Clinical symptoms comparable coronavirus COVID-19 COVID-19 pandemic development dose doses ENhance evaluated expectation Fc-fusion FcγR fusion protein greater huACE2 human IgG1 Fc IgG titers immunogenic immunogenicity Infection Infectious disease K18 live SARS-CoV-2 maintain mice Neonatal neutralization neutralizing IgG titer Neutralizing titer NHP NHPs non-human primate non-human primates pandemic phase preclinical studies preclinical study Prophylaxis receptor Receptor binding domain Region SARS-CoV-2 viral infection SARS-CoV-2 virus single dose South Spike protein subunit Subunit vaccine Support the SARS-CoV-2 USA-WA1/2020 Vaccine Vero-E6 cells Viral viral infection viral spike protein viral strain viral variant virus virus infection [DOI] 10.1016/j.vaccine.2021.09.077 PMC 바로가기 [Article Type] Article
Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccineCOVID-19 회복 사례 및 비활성화된 COVID-19 백신인 Covaxin의 수혜자의 혈청을 사용한 VUI B.1.1.28 P2 변이체의 중화Article Published on 2021-10-112022-09-11 Journal: Journal of Travel Medicine [Category] MERS, SARS, 변종, 진단, [키워드] B.1.1.28 B.1.1.28.2 Covaxin COVID-19 COVID-19 vaccine inactivated individual natural infection neutralization Neutralizing titer recipient reductions in SARS-CoV-2 sera shown Vaccine variant [DOI] 10.1093/jtm/taab077 PMC 바로가기 [Article Type] Article
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccinationResearch Article Published on 2021-09-032022-10-28 Journal: Science Advances [Category] COVID-19, [키워드] B.1.1.7 B.1.351 binding binding kinetics circulating Cohort convalescent COVID-19 patient COVID-19 convalescent patient description detectable evade exhibited hospitalized patient human immunity humoral immune response implication individuals Infection monoclonal natural infection neutralization Neutralizing neutralizing antibody Neutralizing titer P.1 Patient Pfizer-BioNTech pre-existing immunity PROTECT recipient reduced reduction in reductions in SARS-CoV-2 SARS-CoV-2 variant spike subsequent susceptibility vaccination Vaccine vaccinee VoC VOCs while with COVID-19 [DOI] 10.1126/sciadv.abj5365 PMC 바로가기 [Article Type] Research Article